Skye Bioscience enters up to USD 22 million equity line with Redmile affiliate in unregistered share sale

• Skye Bioscience entered an equity line of credit with Redmile affiliate Redmile Biopharma Investments III for up to USD 22 million.
• Sales will be unregistered under Securities Act Section 4(a)(2), using common stock or non-voting common stock convertible 1-for-1.
• Monthly issuances capped at USD 2 million, with pricing tied to the PIPE price or market price, subject to a 10% floor discount.
• Deal includes a warrant sized at USD 5 million divided by the PIPE price, exercisable Jan. 1, 2027 through Jan. 1, 2030.
• ELOC drops dollar-for-dollar if funded PIPE proceeds exceed USD 103 million, falling to zero if the funded amount reaches USD 125 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-058605), on August 24, 2026, and is solely responsible for the information contained therein.